Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (39)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lissoni, A.
Right arrow Articles by Mangioni, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lissoni, A.
Right arrow Articles by Mangioni, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:861-863, 1996
© 1996 European Society for Medical Oncology

brief-report

Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer

A. Lissoni, G. Zanetta, G. Losa, A. Gabriele, G. Parma and C. Mangioni

Department of Obstetrics and Gynecology, S. Gerardo Hospital, III branch of University of Milan Monza, Italy

Correspondence to: Gerardo Zanetta, MD Gynecologic Surgery Eisenberg 5A, Mayo Clinic 200 1st Street S.W. Rochester, MN 55905, USA

OBJECTIVE:: to evaluate the antitumour activity of paclitaxel in patients with endometrial cancer pretreated with cisplatin, doxorubicin and cyclophosphamide (PAC).

MATERIALS AND METHODS:: Eligible patients had complete initial surgery, expected survival i3 months, performance status I 1, measurable or evaluable disease. Paclitaxel was given over three hours at the dose of 175 mg/m2, repeated every 3 weeks. Tumour response was first evaluated after 3 cycles. A maximum of 10 cycles was given in responders.

RESULTS:: 19 patients entered the study and a total of 105 cycles were administered. Complete and partial responses were achieved in 2 and 5 patients, respectively, for an overall response rate of 37% (95% CI: 16%–62%). The response rate in patients refractory to platinum was 22% One patient is alive without evidence of disease 16 months after the start of treatment. The most common side effects were mild to moderate myalgia and peripheral neuropathy, which occurred in 31% and 47% of patients, respectively. In only 1 patient treatment had to be discontinued because of severe myalgia.

CONCLUSIONS:: Paclitaxel is active in patients with endometrial cancer pretreated with PAC. Further studies with paclitaxel incorporated in the initial treatment for advanced disease are warranted.

chemotherapy, cisplatin, endometrial cancer, paclitaxel, survival


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Humber, J. Tierney, R. Symonds, M Collingwood, J Kirwan, C Williams, and J. Green
Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration
Ann. Onc., March 1, 2007; 18(3): 409 - 420.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. F. Fleming, V. L. Filiaci, R. C. Bentley, T. Herzog, J. Sorosky, L. Vaccarello, and H. Gallion
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study
Ann. Onc., August 1, 2004; 15(8): 1173 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. F. Fleming, V. L. Brunetto, D. Cella, K. Y. Look, G. C. Reid, A. R. Munkarah, R. Kline, R. A. Burger, A. Goodman, and R. T. Burks
Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
J. Clin. Oncol., June 1, 2004; 22(11): 2159 - 2166.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. J. Hoskins, K. D. Swenerton, J. A. Pike, F. Wong, P. Lim, C. Acquino-Parsons, and N. Lee
Paclitaxel and Carboplatin, Alone or With Irradiation, in Advanced or Recurrent Endometrial Cancer: A Phase II Study
J. Clin. Oncol., October 15, 2001; 19(20): 4048 - 4053.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. F. Fleming, J. M. Fowler, S. E. Waggoner, L. J. Copeland, B. E. Greer, I. Horowitz, G. Sutton, R. J. Schilder, P. M. Fracasso, H. G. Ball, et al.
Phase I Trial of Escalating Doses of Paclitaxel Combined With Fixed Doses of Cisplatin and Doxorubicin in Advanced Endometrial Cancer and Other Gynecologic Malignancies: A Gynecologic Oncology Group Study
J. Clin. Oncol., February 15, 2001; 19(4): 1021 - 1029.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.